Inhibition of interleukin-1 with rilonacept is not effective in cold urticaria-Results of a randomized, placebo-controlled study.

"CONFLICT OF INTEREST STATEMENT Hanna Bonnekoh received honoraria (advisory board, speaker) from AbbVie, Intercept Pharma, Novartis, Sanofi‐Aventis and Valenza Bio Inc. Outside the submitted work. Monique Butze has no conflict of interest. Sebastian Spittler has no conflict of interest. Petra Staubach received honoraria (advisory board, speaker) from AbbVie, Allergika, Almirall‐Hermal, Amgen, Beiersdorf, Biocryst, BMS, Boehringer‐Ingelheim, Celgene, CSL‐Behring, Eli‐Lilly, Galderma, Hexal, Janssen, Klinge, LEO‐Pharma, LETI‐Pharma, L´Oreal, Novartis, Octapharma, Pfizer, Pflüger, Pharming, Pierre Fabre, Regeneron, Takeda, Regeneron, Sanofi‐Genzyme und UCB Pharma outside the submitted work. Karsten Weller is or recently was a speaker and/or advisor for and/or has received research funding from BioCryst, CSL Behring, Moxie, Novartis, Shire/Takeda, and Uriach. Jörg Scheffel has conducted studies for, received research funds/was advisor for Allakos, Ascilion, AstraZeneca, CSL Behring, Escient, LeoPharma, Novartis, Sanofi, Third Harmonic Bio, ThirdRock, ThermoFisher, all outside the submitted work. Marcus Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Astria, Allakos, Alnylam, Amgen, Aralez, ArgenX, AstraZeneca, BioCryst, Blueprint, Celldex, Centogene, CSL Behring, Dyax, FAES, Genentech, GIInnovation, GSK, Innate Pharma, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie, Novartis, Pfizer, Pharming, Pharvaris, Roche, Sanofi/Regeneron, Shire/Takeda, Third Harmonic Bio, UCB, and Uriach. Karoline Krause is or recently was a speaker and/or advisor for, and/or has received research funding from Berlin Chemie, Novartis and Takeda outside the submitted work."

"We thank Melanie Timmler for excellent technical assistance. This investigator‐initiated trial was supported by Regeneron Pharmaceuticals."

"Clinical Trial Registration EudraCT number: 2012‐005726‐30. ClinicalTrials.gov identifier: NCT02171416."